Reiterates 2025 guidance of LINZESS U.S. net sales of $800-$850 million and total Ironwood revenue of $260-290 million LINZESS (Iinaclotide) EUTRx prescription demand growth in Q1 2025 of 8% year-over-year; in line with full-year expectations Raises adjusted EBITDA to greater than $105 million for 2025 BOSTON / Apr 25, 2025 / Business Wire / Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing... Read More